Pitofsky Jason sold 108 shares of REGENERON PHARMACEUTICALS, INC. at $944.22 for −$102k on Nov 4, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SVP Controller
SVP Controller
Filed Nov 6, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$101,975.76Shares × reported price
Shares traded
108Common Stock
Price per share
$944.22Reported price. Read footnotes for ranges.
% of reported position traded
2.45%This security and ownership context
Holdings after
4,307Direct
Trade date
Nov 4, 2026Sell
Filed
Nov 6, 2026, 4:01 PM ET2-day reporting delay
Accession
0002009236-26-000003Code S · Transaction 394561
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 4,415 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

REGN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
REGN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −19%1w ago −10%1d ago +7.6%
Returns since7d +5.7%30d90d180d1y

Footnotes in full

F1: Represents volume-weighted average price of sales of 439 shares of Company stock on November 4, 2026 at prices ranging from $939.10 to $939.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price. F2: Represents volume-weighted average price of sales of 575 shares of Company stock on November 4, 2026 at prices ranging from $940.15 to $940.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price. F3: Represents volume-weighted average price of sales of 982 shares of Company stock on November 4, 2026 at prices ranging from $941.08 to $941.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price. F4: Represents volume-weighted average price of sales of 1,215 shares of Company stock on November 4, 2026 at prices ranging from $942.00 to $942.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price. F5: Represents volume-weighted average price of sales of 529 shares of Company stock on November 4, 2026 at prices ranging from $943.00 to $943.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price. F6: Represents volume-weighted average price of sales of 108 shares of Company stock on November 4, 2026 at prices ranging from $944.00 to $944.34. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price. F7: Represents volume-weighted average price of sales of 179 shares of Company stock on November 4, 2026 at prices ranging from $950.45 to $950.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price. F8: The stock option award vested in four equal annual installments, commencing one year after the date of grant.